Group 1 - The report highlights the selection of 94 companies in the North Exchange, covering various sectors including high-end equipment manufacturing, TMT, chemical new materials, consumption, and biomedicine, with a focus on new productivity companies [2][11][19] - The report emphasizes the importance of specialized and innovative companies, particularly "little giant" enterprises, in driving the new productivity construction [2][3][19] - The five selected companies for this report are Ruijian Medical, Kanghua Co., Tongbao Optoelectronics, Zuxing New Materials, and Peicheng Technology, with an average revenue of 626 million yuan and an average net profit of 95.72 million yuan for 2024 [4][19][20] Group 2 - Ruijian Medical specializes in blood purification products, achieving a revenue of 483 million yuan and a net profit of 127.93 million yuan in 2024, with a gross margin of 51.05% [4][28][30] - Kanghua Co. focuses on POCT in vitro diagnostics, reporting a revenue of 728 million yuan and a net profit of 125.07 million yuan in 2024, with a gross margin of 66.68% [4][35][40] - Tongbao Optoelectronics, which specializes in automotive lighting components, achieved a revenue of 588 million yuan and a net profit of 83.09 million yuan in 2024, reflecting an 11.02% increase in revenue [4][39][40] - Zuxing New Materials is an internationally recognized aluminum pigment manufacturer, with a revenue of 707 million yuan and a net profit of 58.72 million yuan in 2024 [5][39][40] - Peicheng Technology, a third-party BMS "little giant," reported a revenue of 733 million yuan and a net profit of 93.44 million yuan in 2024 [5][39][40]

招股书显示，沛城科技是定位于锂电新能源行业的局部电路增值服务商，在锂电池泛应用化趋势背景下，围绕新能源行业的电池、电源、电驱和电动车关键 零部件需求，专业从事第三方电池电源控制系统（BMS、PCS等）自主研发、生产及销售，并提供以集成电路、分立器件为核心的元器件应用方案。 5月23日，根据北交所公开发行并上市信息，深圳市沛城电子科技股份有限公司（沛城科技）北交所IPO已获受理。 需要注意的是，本次冲击上市沛城科技拟募集资金5亿元，扣除发行费用后拟投资于电池与电源控制系统产能提升项目、研发中心建设项目、补充流动资金 项目，其中，6200万元用于补充流动资金。 不过，沛城科技并不缺钱，报告期（2022年至2024年）各期末货币资金均大幅增长，分别为6027.23万元、1.32亿元、2.3亿元，且基本上为银行存款。 沛城科技拥有15项发明专利及166项软件著作权，实现电池荷电状态（SOC）估算误差低于2.5%，循环寿命提升超20%，技术指标领先行业。目前产品已批 量供应比亚迪、欣旺达、科士达等头部企业，客户涵盖全球储能锂电池出货量前十厂商中的6家，2024年第三方储能BMS出货量位列全国第四。 不过，由于欧洲能源价 ...

Group 1 - During the week of May 19 to May 25, four new IPO applications were accepted by the Shanghai and Shenzhen stock exchanges, while one application was terminated [1][2] - The four companies include Changyu Group applying for the Shanghai main board, Shenglong Mining Group for the Shenzhen main board, and Peicheng Technology and Kanghua Biomedical Technology for the Beijing Stock Exchange [1][2] - The terminated application was from Jiayuan Technology, which had been under review for nearly two years before withdrawing [1][5] Group 2 - Peicheng Technology, which specializes in battery management systems, reported a declining revenue trend from 850 million yuan in 2022 to 733 million yuan in 2024 [3] - The company's net profit also showed a decrease, with figures of 92.42 million yuan in 2022 and 93.44 million yuan in 2024 [3] - Peicheng Technology's gross margin decreased from 30.06% in 2022 to 28.57% in 2024, indicating potential risks related to product revenue structure changes [3] Group 3 - Jiayuan Technology's revenue heavily relies on State Grid, with sales to the company accounting for approximately 70% of its total revenue [5][6] - The company's revenue figures were 248 million yuan in 2020, 528 million yuan in 2021, and 581 million yuan in 2022, showing a slowdown in growth [6] - Jiayuan Technology faces risks related to the iteration of its smart terminal products and the pace of its digital solution implementations [7][8]